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A 4-year-old white boy presented to Stony Brook University Hospital
for the first time at 3 weeks of age with failure to thrive, He was born
at 40 weeks gestation by caesarean section (for breech presentation);
the birth weight was 3.80 kg. He was discharged at 5 days of age. At 2
weeks of age, he developed loose, watery stools approximately 4 times
daily. At that time the infant was receiving Enfamil, 1.0 to 1.5 oz, every
3 to 4 hours. Five days prior to his first admission to the hospital, the
patient had been given instead a soy formula; the diarrhea ceased, but
formula intake remained at 1.0 to 1.5 oz every 3 to 4 hours. Occasional
postprandial vomiting was noted at that time. On the day prior to
admission, the patient's weight decreased to 3.66 kg, and he was
admitted for evaluation.
Physical examination on admission revealed a temperature of 98°F;
respiratory rate, 32 breaths/mm; heart rate, 164 beats/mm; blood
pressure, 79/54 mm Hg; and weight, 3.35 kg. The baby was alert, well
hydrated, and in no distress; the remainder of the physical examination
was unremarkable. Serum biochemical data on admission showed a
sodium of 135 mEq/liter; potassium, 6.9 mEq/liter; chloride, 106 mEq/
liter; bicarbonate, 15 mEq/Iiter; BUN, 74 mg/dl; and creatinine, 2.0
mg/dl. Cultures of urine, blood, and cerebrospinal fluid were negative.
The initial serum calcium level was 8.6 mg/dl; serum phosphorus, 6.5
mg/dl; and serum alkaline phosphatase, 292 IU. A renal ultrasound
showed bilaterally small, echogenic kidneys, with the right kidney
measuring 3 cm in length and the left kidney measuring 4 cm in length
(normal length, 5.0 0.4 cm). A DTPA renal scintiscan disclosed 2
small, poorly functioning kidneys. Voiding cystourethrogram revealed
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a normal bladder and urethra. An MRI scan showed bilateral small
kidneys with loss of corticomedullary differentiation.
The clinical diagnosis was renal insufficiency secondary to bilateral
renal dysplasia. The formula was changed to PM 60/40, which is low in
potassium and phosphorus; sodium bicarbonate also was prescribed at
a dose of 2.5 mEq/kg/day in 4 divided doses. Calcium carbonate (1250
mg/day) was added to the formula, and dihydrotachysterol (DHT), 0.25
jsglday, was prescribed. The baby's formula was supplemented with
polycose and medium-chain triglycerides to achieve a final caloric
concentration of 34 calories/30 cc, and he was given 130—150 calories/
kg/day. While in the hospital, the infant gained 0.3 kg, the BUN
decreased to 25 mg/dl, and the serum creatinine level decreased to 1.4
mg/dl. The serum calcium level increased to 10.8 mg/dI, and the serum
phosphorus decreased to 4.9 mg/dl. Two weeks after discharge (at age
5 weeks), his weight had increased to 4.7 kg (75th centile); his length
was 55 cm (50th centile). One month later (at age 9 weeks), he weighed
5.0 kg and was 55.4 cm in length.
At 13 months of age, he was doing well clinically; his weight was 10.6
kg (50th centile), length was 74.3 cm (10th centile), and head circum-
ference was 46 cm (25th centile). The BUN was 80 mg/dl; serum
creatinine, 2.1 mg/dl; serum calcium, 10.0 mg/dl; and serum phospho-
rus, 6.0 mg/dl. The hematocrit was 31%. At 16 months of age, the
patient's weight was 10.7 kg, length was 76.5 cm, and head circumfer-
ence was 47 cm. His weight had declined from the 50th to 30th centile;
his centiles for length and head circumference were stable. The BUN at
that time was 75 mg/dI, and the serum creatinine level was 1.9 mgldl.
Dietary intake of calories, protein, and fat was well above the recom-
mended daily allowance (RDA) parameters for his age, as assessed by
a 3-day home dietary diary. When he was 19 months old, his weight was
11 kg (25th centile), length was 79.7cm (10th centile), and the BUN and
serum creatinine levels were 46 mg/dl and 2.1 mgldl respectively. At 26
months of age, his weight was 11.6 cm (5th centile); height, 80.4 cm (<
3rd centile); and head circumference, 48 cm (10th centile); the serum
creatinine level was 1.8 mgldl. Thyroid function studies (TSH, T3RU,
T4, and FTI) were normal. Growth hormone (GH) evaluation at that
time included nocturnal sampling (GH increased from 3.9 ng/ml to 33
ng/ml between 2400 hr and 0400 hr) and a propranololfL-dopa stimula-
tion test, which revealed GH levels of 18 ng/ml and 23.0 ng/ml at 60 and
90 mm following stimulation. Blood glucose and insulin levels disclosed
no carbohydrate intolerance.
Discussion
DR. RICHARD N. FINE (Professor and Chairman, Depart-
ment of Pediatrics, State University of New York at Stony
Brook, Stony Brook, New York): Growth retardation is one of
the serious clinical manifestations associated with irreversible
renal insufficiency in infants, children, and adolescents. Al-
though the relationship was first noted at the end of the last
century [1], the availability of dialysis and renal transplantation,
which could prolong the lives of children who developed
end-stage renal disease (ESRD), focused attention on the med-
ical and psychosocial consequences of the growth retardation
that accompanies chronic renal failure [2, 3].
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Despite extensive investigative efforts (detailed in four inter-
national conferences beginning in 1977) [4—71, the precise cause
of growth retardation in children with chronic renal failure has
not been defined. Multiple factors have been implicated [81: (1)
age at onset of chronic renal failure; (2) concomitant acidosis;
(3) progressive renal osteodystrophy; (4) inadequate caloric
intake; and (5) perturbations of various growth factors. In
addition, repetitive episodes of electrolyte imbalance in infants
with dysplastic renal disease also have been identified as
contributing to growth retardation in these children [9].
Correction of acidosis, prevention and/or treatment of renal
osteodystrophy, provision of adequate caloric intake, and cor-
rection of any electrolyte abnormalities have not uniformly
achieved optimal linear growth in children with chronic renal
failure, as today's case illustrates. That growth retardation
persists despite the presumed correction of these untoward
factors is indicated by the recent report of the North American
Pediatric Renal Transplant Cooperative Study (NAPRTCS)
[10]. Of more than 1500 pediatric recipients of renal allografts
(who received a renal transplant since January 1987), the
majority manifested significant growth retardation at the time of
transplantation (< 5th percentile on the growth curve and/or a
standard deviation score (SDS) more negative than minus 2.00).
Moreover, 25% of these patients had not previously received
dialysis.
Reasoning from these observations, investigators have con-
cluded that perturbations of the various growth factors and their
end-organ effects are likely candidates to explain the growth
retardation, and much information has been assembled to
assess this possibility. Growth hormone levels are elevated in
children with chronic renal failure [11]. Measurement of so-
matomedin-C (insulin-like growth factor, IGF) by bioassay
revealed low levels both in adults and children with chronic
renal failure [12, 131, whereas radioimmunoassay revealed
elevated levels of IGF in children with chronic renal failure [141.
This discrepancy led Phillips et alto conclude that an inhibitor
of somatomedin activity is present in uremia [15]. Utilizing
newer techniques (radioimmunoassay and radioreceptor assay
following acid chromatography), Powell and coworkers demon-
strated normal IGF-1 levels, slightly elevated IGF-2 levels, and
elevated IGF binding protein (IGF-BP) levels in children with
chronic renal failure [161. A theoretical possibility is that
IGF-BP binds circulating free IGF-l levels and functions as a
uremic inhibitor.
The presence of elevated growth hormone levels in growth-
retarded children with chronic renal failure dampened interest
in the potential therapeutic efficacy of exogenous GH in revers-
ing the defect. However, a report by Mehls and Ritz in the early
1980s utilizing porcine GH in the uremic (/6 nephrectomy) rat
model demonstrated that giving short-term (2 weeks) intraperi-
toneal porcine GH in supraphysiologic doses increased the
animals' linear growth and weight [17]. Treatment did not
totally correct the growth retardation associated with uremia in
the uremic rat model, but a significant increment was obtained.
Therefore, other unidentified factors contributed to the growth
retardation in this animal model. Subsequent studies utilizing
recombinant human growth hormone (rhGH) and rat GH in the
uremic rat model confirmed that a significant increase in growth
velocity was obtained [18—201. The study by Nakano and
colleagues was particularly important because it demonstrated
Table 1. rhGH Treatment in children with chronic renal failure
Reference # of pts prior 12 months rhGH 12 months
Koch et a! [22] 5 4.9 1.4 8.9 l.2'
Tonshoffet al [23] 9 44 8.oa
Wilson et alb [24] 2 — 94
Rees et al [25] 6 4.8' lo.7
a Cmlyr.
b Cystinosis.
that the salutary effects of GH treatment accrued despite the
presence of a protein-restricted diet [20]. Consequently, if
protein restriction decreases the rate of progression of chronic
renal failure, the concomitant use of rhGH with protein restric-
tion in growth-retarded children would be expected to be
therapeutically efficacious.
Stimulated by the results reported in the uremic rat model,
we initiated a phase-I study in the latter half of 1986 using
supraphysiologic doses of rhGH in 5 growth-retarded children
who had chronic renal failure (GFR, 14—30 ml/min/l.73 m2). We
administered the rhGH subcutaneously, 0.125 mg/kg thrice
weekly, and observed a significant increase in the annualized
growth velocity following 6 months of treatment: 4.9 1.4
cm/yr to 10.1 2.0 cm/yr, (P < 0.01) [21]. Subsequent studies
reported (1) by Koch et al of the actual one-year data from 5
phase-I patients [221, (2) by Tonshoff et al of 9 patients, 8 of
whom had ESRD and were undergoing continuous ambulatory
peritoneal dialysis (CAPD) [23], (3) by Wilson et al of 2 patients
with cystinosis [24], and (4) by Rees et a! of 6 patients with
chronic renal failure [251 all demonstrated an increased rate of
growth following one year of rhGH treatment compared with
that achieved during the year prior to treatment (Table I).
The number of patients enrolled in our phase-I study has
increased to 11, and the length of followup has been extended
from 18 months to 4 years (Table 2). Following a report that
daily injections (but the same weekly dose) of rhGH in children
with GH deficiency increased growth velocity over that ob-
tained with the thrice-weekly schedule [26], we gave the pa-
tients in our phase-I study a daily dose of rhGH (0.375 mg/kg!
week). Let's look at a variety of clinical parameters to assess
the success of the daily rhGH schedule.
Growth hormone levels. Prior to receiving rhGH treatment,
each patient, save one (Patient 9) had either a 24-hour inte-
grated spontaneous GH test (GH levels obtained every 30
minutes during a 24-hour period, Patients 1 through 5) or an
L-dopa/propranolol GH stimulation test (GH levels obtained 60
and 90 minutes following stimulation). In addition, Patients 1
through 5 had the L-dopalpropranolol test after one year of
rhGH treatment and after discontinuing treatment for 10 days.
The results of the L-dopa!propranolol stimulation tests are
shown in Table 3.
Patients 6 and 11 with cystinosis had an abnormal GH
stimulation test; that is, they both failed to achieve a GH level
greater than 10 ng/dl. Similarly, Patient 3 had an abnormal
stimulation test and manifested only one peak between 5 and 7
ng/dl during the 24-hour spontaneous GH secretion test. The
remaining patients demonstrated an adequate response to the
stimulation test (GH level greater than 10 mg/dl).
Growth velocity. During the year prior to rhGH treatment,
the mean SD growth velocity of the 11 patients was 5.4 2.2
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Table 2. Patient data
Duration of
Age treatment
Pt. (yrs) Renal disease (months) SDS
I 6.6 puva 18 —3.36
2 4.9 Dysplasia (BOR) 36 —2.18
3 4.1 PUV 48 —2.16
4 2.9 Dysplasia 48 —3.40
5 3.8 Dysplasia 48 —3.38
6 8.1 Cystinosis 36 —2.17
7 5.8 Dysplasia 36 —2.40
8 16.3 Alagille's syndromea 36 —5.93
9 9.4 Dysplasia 24 —3.34
10 2.5 Dysplasia 24 —2.80
11 10.6 Cystinosis 18 —4.14
mean 6.8 30 —3.21
SD 4.1 12 1.12
a PUV, posterior urethral valves; BOR, brachial otorenal syndrome;
Alagille's syndrome, arteriohepatic dysplasia.
Table 3. L-dopalpropranolol stimulation testa
Serum growth hormone levels
(ngldl)
Pt. 60 mm 90 mm
1 12.6 3.6
2 18.9 15.5
3 6.8 4.5
4 22.2 15.7
5 46.4 19.5
6b 5.3 4.1
7 23.6 12.9
8 18.4 10.1
9 — —
10 24.9 28.4
11b 3.7 2.6
a Baseline tests were performed before initiation of rhGH in Patients
6—11. Studies in Patients 1—5 were performed following one year of
rhGH treatment but after therapy had been discontinued for 10 days.
b Cystinosis.
cm/yr (Table 4). Following rhGH treatment, the mean SD
growthvelocityincreasedto8.9 1.6,7.5 1.8, 7.5 1.6, and
6.9 0.9 cmlyr at 12, 24, 36, and 48 months, respectively. The
increment in growth velocity increased significantly at 12 and 36
months following rhGH treatment, compared with that
achieved during the year prior to treatment.
The lack of significance at 24 months is attributed to the
inclusion of Patient 10. Growth data at 12 to 24 months, when
the patient's chronologic age increased from 3.5 to 4.5 years,
was compared with data from the year prior to treatment, when
the patient's chronologic age increased from 1,5 to 2.5 years.
Since the expected increment was much greater during the
latter time interval, it is not possible to compare actual growth
velocity as an indicator of efficacy, but the improvement in the
SDS is a more valid parameter for comparison.
Improvement in growth velocity was verified in Patient 10 by
the change in standard deviation score following rhGH treat-
ment (Table 5). The mean SDS decreased significantly at all
time intervals following treatment. Of 7 patients treated for 36
months, 5 reached the normal growth centile, defined as above
the 5th centile on the growth curve and an SDS more positive
Table 4. rhGH Treatment in chronic renal failure
Growth velocity
(cm/yr)
Pt. —12 mon 12 mon 24 mon 36 mon 48 mon
I 4.8 8.7
2 6.3 10.7 7.7 .,
3 6.3 7.5 ..L3 14
4 3.0 8.6 8.1 2
5 4.3 9.2 5.6 ..Q
6 5.0 7.2 ..L
7 5.7 8.9 ..14
8 3.0 ...2 4.2 ..2
9 6.7
10 10.7 1L2 1.1
II 3.2
mean 5.4 8.9 7.5 7.5 6.9
SD 2.2 1.6 1.8 1.6 0.9
—12 mon versus P = <0.00005 NS <.008 NS
a Underlined value indicates that the patient received daily rhGH for
the previous 12 months.
than —1.88. Patient 2 actually exceeded the 50th centile on the
growth curve at 36 months, as indicated by a positive standard
deviation score. This level was at the patient's 50th centile for
mid-parental height; therefore rhGH treatment was discontin-
ued at that time because the child's stature was considered
normal for chronologic age at the 50th centile (Fig. 1).
Weight gain and anthropometric measurements. The mean
SD for weight gain following rhGH treatment increased signifi-
cantly from that achieved during the 12 months prior to treat-
ment: from 1.6 0.6 kg/yr to 3.1 0.6 (P = 0.0001), 3.0 0.8
(P < 0.0002), 3.6 1.5 (P < 0.0009), and 3.4 1.0 kg/yr (P
NS) at 12, 24, 36, and 48 months of rhGH treatment, respec-
tively. The mean SD for triceps skinfold thickness (TSF)
decreased significantly at all time intervals, the mid-arm cir-
cumference (MAC) increased significantly at 24 and 36 months,
and the mid-arm muscle circumference (MAMC) increased
significantly at all time intervals following rhGH treatment. The
patients thus demonstrated an increase in muscle mass; conse-
quently, significant anabolism was attributable to the rhGH
treatment in addition to the increment in growth velocity.
Bone age. In general, mean bone age did not increase more
than the advancement in chronologic age; in individual patients,
however, the increase in bone age exceeded the advancement in
chronologic age (Table 6). The ratio of change in height age to
change in bone age was greater than 1.0 in each instance; thus
the increment in height exceeded the expected advancement in
bone age. Therefore, true catch-up growth (defined as an
increase in the SDS for height) occurred, and the increased
growth velocity was not merely an increment in height conse-
quent to advancement in bone age.
Glucose intolerance. At the initiation of the phase-I study, we
were concerned that GH administration would accentuate the
glucose intolerance of uremia. Altered glucose homeostasis
occurs in 30% to 60% of patients with acromegaly [27]. Of
these, 20% develop frank diabetes mellitus [28]. In normal
individuals, high-dose GH administration can lead to increased
fasting blood glucose levels [291 as well as to an increase in
fasting insulin levels [30]. Consequently, we monitored fasting
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Table 5. rhGH Treatment in chronic renal failure
Height standard deviation score (SDS)
Pt. 0 mon 12 mon 24 mon 36 mon 48 mon
1 —3.36 —2.18
2 —2.18 —1.46 —0.69
3 —2.16 —1.89 JJ3 .JLZ2 .JL.2_9
4 —3.40 —2.71 —2.60 L2 J_4
5 —3.38 —2.99 —2.99 L11 ..2.L2
6 —2.17 —1.68 .JJj) Lfi
7 —2.40 —1.65 22 L0
8 —5.93 .5..J.5 ..5.22
9 —3.34 2A4
10 —2.80 L4 L&9
11 —4.14 35
mean —3.21 —2.50 —2.05 —1.51 —1.35
SD 1.12 1.07 1.46 1.64 .95
0 mo yersus P = <.00005 <.0001 <.0003 <.02
a Underlined value indicates that the patient received daily rhGH for
the previous 12 months.
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Fig. 1. Growth curve of Patient 2 before and after treatment with
rhGH. (t.i.w., 3 times weekly.)
and 2-hour postprandial blood glucose and serum insulin levels
serially before and after rhGH administration.
We detected no significant increase in the fasting and 2-hour
postprandial blood glucose and insulin levels following rhGH
treatment. Serial glucose tolerance tests in Patients I through 5
Table 6. rhGH Treatment in chronic renal failure
Pt. 0 months
B
12 months
one age (years
24 months 36 months 48 months
1
2
3
4
5
6
7
8
9
10
11
4.3
3.3
2.9
1.7
2.7
7.5
3.0
9.8
7.2
0.2
8.0
5.4
4.3
3.3
2.2
3.8
8.3
4.2
10.5
8.0
2.0
10.0
4.3
4.5
2.8
4.7
9.4
6.0
14.0
10.5
3.0
5.5
5.5
4.3
5.5
11.5
7.0
14.5
7.0
4.5
7.0
mean
SD
4.6
3.0
5.6
3.1
6.6
3.9
7.7
3.8
6.2
1.4
0 months versus P = <.00005 .0002 .0001 <.02
during the first year of treatment revealed no significant change
in the blood glucose or insulin levels [221. Similarly, other
reports detailing the use of rhGH in children with chronic renal
failure and in those undergoing dialysis revealed no adverse
effects of rhGH treatment on glucose tolerance [23—25].
Serum calcium, phosphorus, and alkaline phosphatase lev-
els. Exogenous [31] and endogenous [32] growth hormone
increases calcium excretion and decreases phosphorus excre-
tion by the normal kidney [31, 32]. We attempted to assess
rhGH's potential for producing perturbations in the serum
calcium and phosphorus levels. In our serial studies, we ob-
served no significant increase in the serum calcium level (Table
7). The mean serum phosphorus level increased significantly at
36 and 48 months, respectively.
Following initiation of our phase-I study, Foremen et al
published a report indicating that the concomitant administra-
tion of rat GH and 1 ,25-dihydroxyvitamin D3 caused severe
hypercalcemia and markedly increased the Uca**/Ucr in the
uremic rat model [33]. These results raised a concern regarding
the potential adverse impact of concomitant rhGH and 1,25-
dihydroxyvitamin D3 treatment on the progressive decline of
renal function in children with chronic renal failure because of
hypercalcemia and increased renal calcium deposition [34]. All
the patients in our study were receiving prophylactic 1,25-
dihydroxyvitamin D3, so we serially assessed the Ua/Ur to
detect hypercalciuria following rhGH treatment. Except for the
2 patients with cystinosis and Fanconi syndrome who had
hypercalciuria prior to rhGH treatment, no patient had a
consistent Ua*/Ur greater than 0.20 (the upper limit of
normal) following rhGH treatment [35]. The dose of rhGH
administered to the patients in our study did not produce
significant hypercalciuria despite concomitant 1 ,25-dihydroxy-
vitamin D3 administration.
The serum alkaline phosphatase level did increase signifi-
cantly with rhGH treatment, however (Table 7). This phenom-
enon also has been noted following rhGH treatment of children
with GH deficiency and is thought to reflect GH's effect on
osteoclastic activity [36].
DIC
rhGH t.i.w.
rhGH Daily
D = Dialysis
DIC Discontinued
T =Transplant
2 3 4 5 6 7 8 9101112131415161718
Age, years
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Table 7. Biochemical dataa
Serum levels 0 months 12 months 24 months 36 months
Calcium, mg/dl 9.7 0.8 9.7 0.5 9.7 0.5 9.9 0.6
Phosphorus, mg/dl
Alkaline,
4.7 1.0
239 104
5.0 1,0 5.1 0.9
315 130" 381 226"
5.2 1.2"
359 156
phosphatase,
U/liter
Cholesterol, mg/dl 191 63 201 41 206 35 217 34
Triglyceride, mg/dl 176 118 154 62 149 56 186 109
a All data reflect the mean so.
b p < 0.05; all other values NS versus 0 months,
Serum cholesterol and triglyceride levels. Hyperlipidemia
with elevated triglyceride levels occurs in approximately two-
thirds of acromegalic patients [371. This increase has been
attributed to reduced activity of hepatic triglyceride lipase and
lipoprotein lipase [38]. Because lipoprotein lipase also is de-
creased in uremia, and because the potential therefore exists for
accentuated perturbations in lipid metabolism in uremic pa-
tients receiving rhGH, we evaluated lipid metabolism in our
patients and, as noted in Table 7, found no significant change in
the serial serum cholesterol or triglyceride levels following
rhGH treatment. Similarly, Tonshoff and colleagues noted no
change in the serum cholesterol, triglyceride, or lipoprotein
profiles (HDL, LDL, VLDL cholesterol) after giving rhGH for
12 months to 10 children with chronic renal failure [391.
Renal function. Exogenous [40] and endogenous [41] growth
hormone increases glomerular filtration rate (GFR) and renal
plasma flow (RPF). Hypophysectomy reverses both phenom-
ena [42]. Because of the concern that rhGH-induced hyperfil-
tration might accelerate the decline in renal function, we
calculated GFR at frequent intervals following initiation of
rhGH treatment.
Although 2 patients (Patients 1 and 2) required initiation of
dialysis following 18 and 30 months of rhGH treatment respec-
tively, we did not observe a significant decline in the calculated
GFR (creatinine clearance) for the group as a whole [44] (Table
8). Similarly, Tonshoff et al observed no change in the slope of
the calculated GFR curve for the year prior to rhGH treatment,
compared with that observed during the year following rhGH
treatment [39]. Utilizing inulin clearance to measure GFR, the
same group observed no significant change following 6 weeks of
rhGH treatment [45].
Haffner and coworkers measured the GFR by inulin clear-
ance in 7 healthy adult volunteers and 7 adults with chronic
renal failure prior to and following 3 days of rhGH administra-
tion [46]. Glomerular filtration rate increased significantly in the
volunteers but not in the adults with chronic renal failure. This
finding was attributed to a lack of renal reserve, which presum-
ably is required for GFR to rise in response to rhGH. Therefore,
although the potential for rhGH-induced hyperfiltration with a
consequent progressive decline of GFR exists, no data to date
demonstrate that such a circumstance has occurred in pediatric
patients with chronic renal failure who have been treated with
rhGH.
The concern about the potential adverse impact of GH-
induced hyperfiltration is supported by data from animal mod-
els, however. Doi et al demonstrated that transgenic mice,
which chronically express excessive GH and GH-releasing
Table 8. Calculated creatinine clearance (ml/min/1.73 m2)
Pt. 0 months 12 months 24 months 36 months 48 months
1 14 13
2 17 18 12
3 16 14 15 10 11
4 14 19 19 14 14
5 30 25 28 24 20
6 64 56 48 45
7 37 52 45 42
8 30 24 22 16
9 26 18 15
10 22 15 15
11 35 27
mean 28 26 24 25 15
15 15 14 15 5
0 months versus P = NS NS NS NS
hormone, have large, abnormal glomeruli with mesangial hy-
percellularity and sclerosis, a triad that progresses to glomeru-
losclerosis [47]. Similarly, Wanke and coworkers recently ob-
served that GH-transgenic mice had a shortened life expectancy
primarily because of renal failure [48]. The renal lesion mor-
phologically was glomerulosclerosis. Consequently, the lack as
yet of any definitive data correlating hyperfiltration with rhGH
treatment of children with chronic renal failure should not make
us complacent; assiduous surveillance for this potential com-
plication is still necessary.
Levels of insulin-like growth factor. In our study, IGF-1
levels significantly increased following rhGH treatment (Table
9). Tonshoff and colleagues reported similar findings, including
an increase in somatomedin bioactivity [23]. Although the
IGF-BP level increased slightly, the rise was considerably less
than the increment in the IGF-l level. Therefore, there was a
substantial net increase in the unbound IGF-1 level. The
authors concluded that the IGF-BP was the "uremic inhibitor"
and that the mechanism for improvement in growth velocity
following exogenous rhGH treatment is attributable to the net
increase in the unbound IGF-1 level, as reflected by the
increase in bioactivity.
What are the potential short-term and long-term benefits of
rhGH treatment in children with chronic renal failure? The
potential short-term benefits of rhGH treatment are: (1) allevi-
ation of the psychosocial consequences of marked impairment
of linear growth and (2) delaying renal transplantation by
eliminating growth retardation as an indication for "pre-emp-
tive" engraftment, which currently accounts for almost one-
quarter of all renal transplants performed in children in the
United States [10]. Although precise data regarding the indica-
tions for pre-emptive transpiantion are not available, it seems
likely that persistent growth retardation is among the more
common reasons for employing this intervention.
The availability of 1 ,25-dihydroxyvitamin D3 for preventing
the development of clinical renal osteodystrophy, rhGH to
correct the growth retardation, and recombinant human eryth-
ropoietin (rHuEpo) to reverse the anemia of chronic renal
failure has the combined potential to delay the clinical need for
dialysis and transplantation and to prolong the duration of
conservative treatment. Patient 3 (Fig. 2) illustrates this; he has
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Table 9. rhGH Treatment in chronic renal failure: IGF-1 levels (U/mi) (Acid chromatography)
Pt. 0 months 6 months 12 months 18 months 24 months 30 months 36 months 48 months
1
2
3
4
5
6
7
8
9
10
11
0.49
0.53
0.36
0.14
0.31
0.21
0.40
0.65
—
0.64
0.18
1.49
1.05
0.48
0.29
0.19
1.02
0.94
1.09
2.72
1.40
0.83
1.36
1.49
0.66
0.78
0.36
0.47
1.44
1.80
2.81
0.96
0.81
0.72
1.47
1.02
0.70
0.57
1.55
1.33
0.69
4.48
0.83
1.30
1.37
1.54
1.00
0.55
0.79
1.01
1.47
3.26
1.07
0.78
0.76
0.56
1.42
1.01
1.56
3.39
1.43
2.66
1.95
1.02
1.47
2.75
1.53
3.36
1.96
1.49
mean
SD
.39
0.18
1.5
0.69
1.18
0.71
1.33
1.10
1.37
0.84
1.32
0.90
1.83
0.66
2.27
0.97
0 months versus P <.002 <.0006 <.002 <.0006 <.002 <.002 NS
had conservative treatment for more than 18 months following
initiation of rHuEpo treatment despite having a GFR compara-
ble to that of Patients 1 and 2, who required therapy for
end-stage renal disease (dialysis); rHuEpo was not yet available
when these patients could have benefited from it. During this
18-month period, continued rhGH treatment has produced
increased height in Patient 3. Perhaps in the future we will be
able to significantly prolong the period of conservative manage-
ment of chronic renal failure by reducing the clinical conse-
quences of uremia in children—renal osteodystrophy, growth
retardation, and anemia.
The long-term benefit of rhGH in children with chronic renal
failure is that rhGH facilitates achievement of the genetic
potential for height by improving the growth velocity to the
extent that patients reach the 50th centile on the growth curve
for mid-parental height. If this goal is achieved prior to the
development of end-stage renal disease, then the possibility of
these children obtaining normal adult heights following dialysis
and/or transplantation will be enhanced. Long-term followup of
the children currently receiving rhGH treatment is required to
determine whether we can help these children reach that goal.
Questions and answers
DR. LEONARD KLEINMAN (Professor of Pediatrics, State
University of New York at Stony Brook, Stony Brook, New
York): It appears that all 3 patients who were treated with
growth hormone for at least 48 months showed a decline in
glomerular filtration rate. Does this make you leery about the
very-long-term effects of growth hormone on renal function?
Also, if growth hormone has an adverse effect on renal func-
tion, do you think it's a direct effect, or might it be mediated by
IGF? Has anyone tried to use IGF itself, rather than GH, to
stimulate growth?
DR. FINE: The clearances that I showed you were calculated
creatinine clearances, which probably are not the optimal
method to use to follow patients serially. We did not use inulin
clearances from the beginning, so we didn't have baseline data
with which to make comparisons when we saw the beneficial
effects of rhGH. Calculated creatinine clearances used in a
controlled study revealed no difference in the decline of renal
function in patients receiving rhGH and the control population
(unpublished data). In our patients treated over 4 years, the
calculated creatinine clearance fell from 15 to 10 ml/min/1.73
m2; we interpreted this change to be the anticipated decline in
renal function and not an accelerated decline secondary to
rhGH. I think your point is well taken, however, and a
controlled study has been initiated in which two-thirds of the
children have been treated with rhGH and one-third have been
treated with a placebo (unpublished data). No statistically
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Fig. 2. Growth curve of Patient 3 before and after treatment with
rhGH and rHuEpo. (t.i.w., 3 times weekly.)
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significant difference was apparent in the calculated creatinine
clearance data from the subjects given placebo versus the
rhGH-treated group over a 2-year period. To my knowledge,
IGF- 1 is available for experimental trials in animals but has not
yet been approved for use in humans with renal failure. My
colleagues in endocrinology might want to comment.
DR. SANDRA BLETHEN (Associate Professor of Pediatrics,
State University of New York at Stony Brook): Several compa-
nies throughout the world are now making IGF- 1. Clinical trials
are beginning to assess the effects of IGF- 1 in patients who have
no growth hormone receptors—the so called Laron-type dwarf
[49]. IGF-1 also has been used to treat hyperglycemia and
growth failure in a patient with Mendenhall's syndrome, which
involves a severe defect in the insulin receptor [50]. So IGF- 1
presumably could be tried in children with chronic renal failure.
DR. FINE: I think your other point is also very well taken.
The data in the transgenic mice suggest that the IGF- 1 does not
produce the kind of sclerosis that either growth hormone or
growth-hormone-releasing hormone does. We are in the pro-
cess of setting up studies to look at the effects of IGF-l in the
uremic rat model. I think it is important because IGF-l might
have less of an adverse impact on renal function than rhGH
does if, indeed, rhGH has any adverse clinical impact.
DR. JORDAN J. COHEN (Dean, School of Medicine, State
University of New York at Stony Brook): You noted that in rats
with chronic renal failure, the administration of growth hor-
mone did not normalize growth, and you cited this result to
suggest that factors other than GH deficiency might be involved
in the growth retardation seen with chronic renal failure. How
do we know that sufficient hormone was given? Has a dose-
response curve been established in the rat or, for that matter, in
the children that you've treated with rhGH? Also, can you
elaborate on how rhGH stimulates growth? Are all of its effects
mediated by IGF? And how does IGF work at the level of
cartilage and bone to promote growth?
DR. FINE: I think I will defer to my endocrine colleagues to
comment on the precise mechanism of action of IGF. Presum-
ably, growth hormone stimulates IGF production. Whether it
stimulates circulating IGF or stimulates local paracrine produc-
tion, and whether growth of cartilage is enhanced only by local
stimulation of IGF, I don't know. Perhaps Dr. Blethen could
give us an answer.
With regard to the dose-response relationship, a similar
dosage was used in all the rat studies, and only short-term
studies were performed. In our studies, we have only used one
dose. One of the questions that obviously needs to be answered
is whether a lower dose will produce the same effect as the
higher dose. Studies are planned to address this issue; it is not
only important because of the potential for adverse side effects
that potentially could be minimized by a lower dose, but also
because growth hormone is very expensive. At the moment,
however, no dose-response data are available.
DR. COHEN: Based on the current costs and dosage schedule
of rhGH, how expensive would it be to treat a child for one
year?
DR. FINE: The cost is probably somewhere between $12,000
to $18,000 per year. As a matter of fact, it might even be more
than that, because we are using a higher dosage than that used
to treat children with OH deficiency. A more accurate estimate
might be $20,000 to $25,000 per year.
DR. BLETHEN: I have two comments. First, one of the other
things that GH does is regulate the IGF-binding proteins. In
particular, growth hormone suppresses the levels of the IGF
BP-1, the unsaturated binding protein [51]. So, GH also might
increase the bioavailability of IGF by suppressing the binding
protein. Second, the role of Gil and IGF on bone growth has
been studied, and some good animal data suggest that growth
hormone promotes growth and cell division of the undifferen-
tiated stem cell, whereas IGF-l promotes growth and cell
division of the differentiated cell [52]. So, in fact, growth
hormone has both direct and indirect effects on cartilage
growth.
Da. FINE: Tonshoff and colleagues from Heidelberg mea-
sured IGF- 1 and the binding protein before and after rhGH
administration and found that the levels of both IGF-l and the
binding protein increased, but that the net effect was more free
IGF-l [231. Your hypothesis that net, free IGF might play at
least a partial role is reasonable.
DR. ROBERT WEISS (Director of Pediatric Nephrology, New
York Medical College, Valhalla, New York): I would like to
raise a concern about the effects of a rapid increase in growth
velocity on the course of metabolic bone disease. Most patients
with chronic renal failure experience a modest increment in
growth velocity as they approach puberty, and that is when we
begin to see the development of slipped capital-femoral epiphy-
sis. I've seen this complication in several pre-pubertal patients
with suboptimal control of their renal osteodystrophy. Have
you encountered the same thing?
Da. FINE: That is an excellent question. The development of
slipped capital-femoral epiphysis has been described in children
without chronic renal disease who were given rhGH. One
recent report described a child with GH deficiency who was
treated with rhGH and who developed a slipped capital-femoral
epiphysis [53]. All our patients have been treated with vitamin
D and have had no clinical or radiologic evidence of overt renal
osteodystrophy when they were treated with rhGH. We fol-
lowed these children serially with bone radiographs. No data
are available on the effect of rhGH on renal osteodystrophy in
patients with chronic renal disease; studies will need to be done
in the future. Clinically, we have no evidence of progression of
the renal bone disease in the children we followed.
DR. YELLESHPUR JAYARAM (Director, Child Health, Suffolk
County Health Department, Hauppauge, New York): Do pa-
tients who respond well to rhGH experience a change in blood
pressure?
DR. FINE: None of our patients has developed hypertension
subsequent to rhGH treatment. However, none of these pa-
tients were hypertensive beforehand and all had some form of
renal dysplasia. This group of pediatric patients rarely has
hypertension in conjunction with their chronic renal disease, so
these children probably are at a lower risk for this potential
complication of rhGH treatment. In the patients with renal
allografts whom I have treated with growth hormone, I have not
encountered an rhGH-related increment in hypertension. I do
think hypertension is a concern, however, because sodium
retention can occur during treatment with rhGH.
DR. EDWARD NORD (Associate Professor of Medicine, State
University of New York at Stony Brook): I have a three-part
question. First, given that IGF is thought to work at the local
level where it is released, what can one learn from measuring
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plasma IGF-l levels? My second question has to do with the
possible role of IGF in the absence of growth hormone. In the
kidney, cells of the inner medullary collecting duct can make
IGF by a process independent of growth hormone. Might this
be true of bone? My third question relates to the patients you
described who received both erythropoietin (rHuEpo) and
rhGH and in whom the need for dialysis appeared to be delayed
significantly. Are you suggesting that this treatment retarded
the decline in renal function?
DR. FINE: I'll ask Dr. Gelato to answer your first question in
a moment. I am not suggesting that rhGH has a salutary effect
on GFR, but I am saying that in pediatric patients, the impetus
to initiate dialysis typically entails a number of considerations:
typical symptoms of uremia, significant renal osteodystrophy
that has been unresponsive to treatment, and significant growth
retardation in children who are otherwise doing well. When
transplantation is undertaken without previous dialysis, it is
termed pre-emptive. As a matter of fact, according to the latest
report of the North American Pediatric Renal Transplant Co-
operative Study, which has enrolled between 1500 and 2000
pediatric renal transplant recipients in this country since 1987,
almost one-quarter of all the renal transplants in pediatric
patients are pre-emptive. Although we don't know for sure, the
presumption is that poor growth is the major reason for pre-
emptive transplantation in these children. All other therapeutic
maneuvers have failed, and transplantation is seen as the
answer to resolving the growth retardation. I am suggesting that
treatment with rhGH might offer an alternative to pre-emptive
renal transplantation for the growth-retarded child with chronic
renal disease. Moreover, experience with rHuEpo suggests that
many of the symptoms previously attributable to uremia—for
example, nausea, vomiting, lethargy, unwillingness to go to
school—in pediatric patients are in fact related to anemia. If we
can correct the anemia, prevent the bone disease, and sustain or
improve growth, which are the major factors that have precip-
itated decisions to initiate dialysis in the past, we might be able
to obviate the need to initiate dialysis as early as we have been.
DR. MARIE GELATO (Associate Professor of Medicine, State
University of New York at Stony Brook): Insulin-like growth
factors work both by endocrine and autocrine/paracrine mech-
anisms. Just how circulating levels of IGF-1 relate to tissue
levels, however, is not really clear. I don't think anybody
knows the exact mechanisms yet, but tissue levels probably are
just as important, if not more important, than circulating levels,
at least in some respects. It is clear that these growth factors
can be made by virtually all tissues of the body because their
corresponding mRNA is found in all body tissues. Growth
hormone not only stimulates the liver to produce and release
IGF-1 into the circulation to act presumably by endocrine
mechanisms, but it stimulates other tissues to produce IGF-1 as
well. Additional factors, such as retinoic acid, TGF-a, and
TGF-f3, also can directly stimulate the production of these
growth factors at the tissue level. Indeed, the regulation of IGF
production in a given organ probably relates to the factors
involved in the overall regulation of that organ's function. So I
think growth hormone plays an important role in IGF regula-
tion, but it probably does not provide the only explanation for
how these factors are stimulated and how they act.
DR. COHEN: Anemia has been thought to participate in
growth retardation in children with chronic renal failure. We've
now had several years of experience with rHuEpo. Do we have
any reliable data on what effect correction of anemia with
rHuEpo has had on growth in the absence of exogenous rhGH?
DR. FINE: Preliminary studies utilizing rHuEpo have not
substantiated any beneficial effect on growth. More extensive
controlled studies in dialysis patients are in progress, and these
should help settle the question.
DR. THOMAS WILSON (Director, Division of Pediatric Endo-
crinology, State University of New York at Stony Brook): Could
you comment on the doses of rhGH that are being used in the
clinical trials? What concentrations of growth hormone are
achieved in the serum of these patients relative to what they
make on their own?
DR. FINE: The dose used has been 0.375 mg/kg/week. On a
daily basis, it is 0.05 mg/kg per dose; if growth hormone is given
only 3 times per week, we give 0.125 mg per dose, which is
somewhat higher than the dosage used in GH-deficient individ-
uals. In pharmacokinetic studies published by Tonshoff and
colleagues, the levels achieved with one dose reached the 60—80
ng/ml range within one or two hours [45]. To my knowledge, no
one has compared different dosages or tried to compare the
dose achieved with endogenous levels of growth hormone. Dr.
Charles Stewart is conducting pharmacologic studies to evalu-
ate serum levels following different methods of growth hormone
administration. We don't yet know whether giving rhGH in the
morning or the evening, or giving two doses a day rather than
one, makes a difference. Obviously, many issues remain to be
addressed, and I suspect that one of the reasons investigators
are not pursuing these issues more vigorously is that the
Federal Food and Drug Administration has yet to approve
rhGH for use in children with chronic renal disease.
DR. CHARLES STEWART (Clinical Assistant Professor, State
University of New York at Stony Brook): You've commented on
the potential effect of rhGH on GFR and the resulting potential
decline in glomerular function. Have studies been done to
assess the effect of rhGH on renal tubular function, in particular
on the renal handling of calcium and phosphorus? I wonder
whether the bone disease that afflicts these children might be
affected by treatment with rhGH.
DR. FINE: I am not aware of any human studies investigating
renal tubular function in patients treated with rhGH.
DR. COHEN: I'm still puzzled about how exogenously admin-
istered rhGH has these dramatic effects when endogenous
levels of the hormone are already elevated. I'm also puzzled
about why endogenous levels are not even higher than they are.
If, as you noted, IGF exerts negative feedback control on
growth hormone, why don't the low levels of bioavailable IGF
result in even higher levels of growth hormone? As you showed
us, other stimuli can provoke further increases in GH.
DR. FINE: We are operating with the hypothesis that the
binding protein is increased relatively less by exogenous rhGH
than is free IGF-l. But I agree that we don't have a very good
explanation for why rhGH improves growth velocity.
DR. GELATO: I agree with you; I don't think there is a good
explanation. It is clear, however, that IGF-binding proteins not
only carry these substances but also can alter their function.
Binding protein-i, BP-l, which is the binding protein that
appears to be increased to the greatest extent in chronic renal
failure, actually can inhibit the action of IGF-l. So not only are
the levels of bioavailable IGF low, there also might exist a
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substance in the circulation that impairs the ability of IGF- 1 to
function normally. Thus, when rhGH is given, the balance of
forces might change. Not only might the amount of IGF-l be
increased, but an inhibitor might be decreased as well, thereby
yielding an enhanced effect. It would be interesting to look at
the effects of rhGH on the IGF-binding protein in these chil-
dren.
In addition, these children might be growth hormone resis-
tant. It is possible that the growth hormone they make is not
biologically active. For example, the growth hormone might be
glycosylated and therefore might not function normally. If this
is the case, exogenous rhGH, which is biologically active, could
enhance growth.
DR. WILSON: Another possible explanation relates to a puta-
tive, short feedback loop by which growth hormone could
inhibit the release of GF-releasing factor. Because of this
feedback loop, the body could maintain a certain damper on
growth hormone secretion, which exogenously administered
rhGH could bypass.
DR. WEiss: Dr. Fine, I know you have done some work on
the effects of rhGH in overcoming the growth retardation that
occurs in children treated with corticosteroids. Would you
comment on the use of rhGH in children who receive steroids
after renal transplantation or who have steroid-dependent ne-
phrotic syndrome?
DR. FINE: We've done some rat studies with Otto Mehis, and
the data will be published shortly in Kidney International. But
let me summarize our work. When we gave the rats steroids,
their growth decreased. When we made them uremic, their
growth decreased further. Giving either group rhGH improved
growth. Theoretically, then, appropriate doses of rhGH might
be able to overcome the effects both of uremia and of steroids.
It appears that, in a rat model, rhGH can overcome the
growth-suppressing effects of steroids. We have treated pediat-
ric renal transplant recipients, and a similar study of transplant
patients was reported from Europe [54]. Indeed, rhGH in-
creases growth velocity in transplant recipients receiving cor-
ticosteroids. However, in a patient with renal functional impair-
ment who is receiving steroids and is given rhGH, growth
velocity does not accelerate as much as in a patient with chronic
renal disease who has the same degree of renal functional
impairment but who is not given steroids. One of the issues that
needs to be resolved is how to adjust the dosage of rhGH for the
additive growth-retarding effects of steroids. With regard to the
nephrotic syndrome, I think patients receiving long-term ste-
roids for the nephrotic syndrome and who have short stature
could benefit from rhGH therapy. Currently ongoing studies are
evaluating the effects of rhGH in asthmatic patients who require
chronic steroid therapy and whose growth is retarded (unpub-
lished data).
DR. Noiw: Is there any evidence or any reason to believe
that either rhGH or IGF would have a therapeutic effect on the
metabolic bone disease that occurs in adults with chronic renal
failure?
DR. FINE: I can't address the issue of bone disease, but! can
address the issue of patients on dialysis who are wasted or are
catabolic. There are preliminary studies using rhGH in hemo-
dialysis patients [55]; rhGH was anabolic in these patients.
Therefore rhGH could be used in an adult dialysis population
with the wasting syndrome to improve anabolism. With regard
to bone disease, I'm not aware that this issue has been
addressed specifically.
DR. COHEN: Have we learned anything about the mechanism
of growth retardation in children with chronic renal failure by
studying the dramatic catch-up growth that often occurs after
successful renal transplantation?
DR. FINE: Yes, we have: the younger the recipient, the more
dramatic the catch-up growth, The patients who are the most
growth retarded also have improved growth, but the amount of
improvement is not as marked as we would like. Consequently,
a significant number of transplant recipients are persistently
growth retarded. Sometimes a growth spurt occurs immediately
after transplantation, but the growth frequently is not sustained.
Reprint requests to Dr. R. Fine, Chairman, Department of Pediat-
rics, Stony Brook Health Sciences Center, Stony Brook, New York
11794, USA
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